All In Biotech

BLA 761408 · Eli Lilly and CO

Onswik

Insulin Efsitora Alfa-Gobe · Subcutaneous

Novel

CDER novel approval, Sep 23, 2026: To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Sep 23, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

5

5 Phase 3, 0 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 23, 2026.

ONSWIK™ is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ONSWIK™ is a long-acting insulin analog indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended for use in patients with type 1 diabetes mellitus due to increased risk of severe hypoglycemia ( 1 ) Limitations of Use ONSWIK is not recommended for use in patients with type 1 diabetes mellitus due to increased risk of severe hypoglycemia. [see Warnings and Precautions ( 5.2 )] .

Mechanism: The primary activity of ONSWIK is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis and enhances protein synthesis. The protracted time-action profile of ONSWIK results from reduced renal clearance due to its relatively large molecular size, inhibition of degradation due to binding at the neonatal Fc receptor, and reduced affinity relative to human insulin for the insulin receptor, which...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 23, 2026 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
2 products under this application
  • ONSWIK · INSULIN EFSITORA ALFA-GOBE 1000 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Prescription
  • ONSWIK · INSULIN EFSITORA ALFA-GOBE 500 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Efsitora Alfa" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 17 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.